Clinical Trials Directory

Trials / Completed

CompletedNCT02157896

Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke

Dynamic Changes of Vascular Endothelial Growth Factor and Endostatin in Association With Circulating Endothelial Progenitor Cells After Acute Ischemic Stroke

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
Shanghai 6th People's Hospital · Academic / Other
Sex
All
Age
45 Years – 74 Years
Healthy volunteers
Not accepted

Summary

Vascular endothelial growth factor (VEGF) and Endostatin (ES) participate angiogenesis after cerebral ischemia. Circulating endothelial progenitor cells (EPCs) also play a crucial role in neovascularization and tissue repair after acute ischemic stroke (AIS). The investigators sought to compare the expression of VEGF and ES in serum and the circulating EPCs in patients after AIS with that of healthy control subjects. The investigators obtained peripheral blood and serum samples from study subjects. EPCs in blood samples from AIS patients and healthy controls were quantified by flow cytometry 1 day, 3 days, 5 days and 7 days after AIS. VEGF and ES were measured by enzyme linked immunosorbent assay at the same time points. The relation between them and the relation of them to prognosis of such patients with acute ischemic stroke were assessed.

Conditions

Timeline

Start date
2013-05-01
Primary completion
2014-04-01
Completion
2014-05-01
First posted
2014-06-06
Last updated
2020-08-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02157896. Inclusion in this directory is not an endorsement.